Bevacizumab mAb-based ELISA Assay

$1,485.00

The Bevacizumab mAb-based ELISA Assay is an enzyme immunoassay for the precise analytical determination of free Bevacizumab in serum and plasma samples.  The Bevacizumab (Avastin®) (mAb-based) ELISA Assay Kit is for research use only and not to be used in diagnostic procedures.

Bevacizumab mAb-based ELISA Assay

The Bevacizumab mAb-based ELISA Assay is For Research Use Only

Size: 1×96 wells
Sensitivity: 2 ng/mL
Dynamic Range: 6 – 200 ng/mL
Incubation Time: 2 hours
Sample Type: Serum, Plasma
Sample Size: 10 µL
Alternative Names: Avastin Assay

Controls Included


Assay Principle

This ELISA is based on Bevacizumab-specific mouse monoclonal antibody (catcher Ab, ImmunoGuide clone MAY-2B5). Standards and diluted samples are incubated in the microtiter plate coated with IG-MAY-2B5 mAb. After incubation, the wells are washed. A horseradish peroxidase (HRP)-conjugated anti-human IgG monoclonal antibody is added and binds to the Fc part of Bevacizumab. Following incubation, wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of Bevacizumab in the sample or standard. Results of samples can be determined by using the standard curve. Binding of Bevacizumab to the solid phase, pre-coated with MAY-2B5, is inhibited by human VEGF-A in a concentration dependent manner. Therefore, the ImmunoGuide Bevacizumab ELISA (mAb-Based) measures the free form of Bevacizumab.


STORAGE AND STABILITY OF THE KIT
The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2–8°C.


Related Products

Rituximab (Rituxan) ELISA (mAb-based) Assay
Golimumab (Simponi®) (mAb-based) ELISA
Certolizumab Pegol (Cimzia) (mAb-based) ELISA Kit

Additional Information

Assay Background


The drug Bevacizumab (trade name Avastin® ) is a recombinant human IgG1::k monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms and it has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration.

The specificity of this test system is achieved by using a monoclonal antibody named “MAY-2B5” for the coating of the microtiter plate. This antibody is specific for Bevacizumab only and does not cross react with other VEGF catchers.

Typical Standard Curve


Bevacizumab mAb-based ELISA Assay

Documents

Product Manual


 

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Publications

Citations


  1. Li J, Gupta M; Jin D, Xin Y, Visich J, Allison DE, Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stag II and III carcinoma of the colon, Cancer Chemother Pharmacol, 2013; 71: 575–580.
  2. Panoilia E, Schindler E, Samantas E, Aravantinos G, Kalofonos HP, Christodoulou C, Patrinos GP, Friberg LE, Sivolapenko G, A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients, Cancer Chemother Pharmacol. 2015; 75:791–803.
  3. Knight B, Rassam D, Liao S, Ewesuedo R. A phase I pharmacokinetics study comparing PF‑06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers, Cancer Chemother Pharmacol. 2016;77:839–846.
  4. Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I,et al., Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia, mAbs. 2015; 7 (3): 630—637.
  5. Han K, Peyret T, Quartino A, Gosselin NH, Gururangan S, Daw NC, Navid F, Jin J, Allison DE. Bevacizumab dosing strategy in pediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol. 2015 Sep 7. doi: 10.1111/bcp.12778.
  6. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Le K, Maia M, Visich JE. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014 Dec;98(12):1636-41.
  7. Bunni J, Shelley-Fraser G, Stevenson K, Oltean S, Salmon A, Harper SJ, Carter JG, Bates DO. Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios. Am J Cancer Res. 2015;5(6):2083-9.
  8. Imbs DC, Négrier S, Cassier P, Hollebecque A, Varga A, Blanc E, Lafont T, Escudier B, Soria JC, Pérol D, Chatelut E. Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer Chemother Pharmacol. 2014 Jun;73(6):1189-96.
  9. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012 Mar;32(3):434-57.
  10. Li Q, Yan H, Zhao P, Yang Y, Cao B. Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Sci Rep. 2015 Oct 27;5:15746. doi: 10.1038/srep15746.
  11. Tang N, Guo J, Zhang Q, Wang Y, Wang Z. Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget. 2015 Oct 20. doi: 10.18632/oncotarget.6184.
  12. Ogata H, Kikuchi Y, Natori K, et al. Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature. Medicine (Baltimore). 2015 Oct;94(42):e1756. doi: 10.1097/MD.0000000000001756.
  13. Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR, et al. Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. Br J Cancer. 2015;113(9):1282-8.
  14. Varol U, Oktay E, Yildirim M, Surmeli ZG, Dirican A, Meydan N, Karaca B, Karabulut B, Uslu R. Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer. Mol Clin Oncol. 2014;2(1):166-170.
  15. Ba J, Peng RS, Xu D, Li YH, Shi H, Wang Q, Yu J. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des Devel Ther. 2015;9:5397-405.
  16. Li X, Huang R, Xu Z. Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis. Sci Rep. 2015 Oct 1;5:14698. doi: 10.1038/srep14698
  17. Gruenberg J, Manivel JC, Gupta P, Dykoski R, Mesa H. Fatal acute cardiac vasculopathy during cisplatin-gemcitabine-bevacizumab (CGB) chemotherapy for advanced urothelial carcinoma. J Infect Chemother. 2015 Sep 27. pii: S1341-321X(15)00198-1. doi: 10.1016/j.jiac.2015.08.015.
    Kaneko E, Niwa R. Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs. 2011;25(1):1-11.
  18. Wong ET, Lok E, Swanson KD. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. Cancer Med. 2015;4(3):383-91.
  19. Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014;20(6):1666-75.
  20. Wang H, Shi J, Wang Q, Li H, Cai K, Hou X, Li T, Zhong Q, Yu D. Assessment of the pre-clinical immunogenicity of a new VEGF receptor Fc-fusion protein FP3 with ELISA and BIACORE. Cancer Immunol Immunother. 2010;59(2):239-46.